OwieClear Type 2 Diabetes Page Accuracy Review
An independent accuracy review of our type 2 diabetes page, judging the core science and drug framing correct but the page underbuilt, and asking for a complications list, fuller diagnostic criteria, hypoglycemia education and a richer treatment narrative.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This review was commissioned as a check on our own work and we are publishing it unedited, including the parts that are unflattering. Its central judgement, that the page was directionally accurate but thin for such a major condition, was correct. We have acted on all seven of its suggestions in update 298, and the notes below record what changed.
- On the first point, a complications section. The page now carries one covering heart disease and stroke, chronic kidney disease, retinopathy, neuropathy, foot ulcers and amputation risk, and fatty liver, with a full deep dive on each and on the screening that catches them early.
- On the second, diagnostic criteria. All four tests and their thresholds now appear on the page: A1C of 6.5 percent or higher, fasting plasma glucose of 126 mg/dL or higher, a 2-hour value of 200 mg/dL or higher, and a random glucose of 200 mg/dL or higher with classic symptoms. The prediabetes ranges are stated alongside, and the requirement to confirm an abnormal result in someone without symptoms has been added, which the review did not ask for but which belongs with the criteria.
- On the third, treatment depth. Hypoglycemia risk with insulin and sulfonylureas is now explicit, as is the instruction not to stop medicines when numbers improve without clinician advice. The drug classes now have a deep dive covering what each one does, which ones protect heart and kidney beyond their glucose effect, and which can cause lows.
- On the fourth, hypoglycemia. This was the most important gap and now has its own deep dive covering who is at risk, the warning signs, the rule of 15, severe episodes and glucagon, driving, and how to stop repeats. The condition page carries the short version.
- On the fifth, heritability. The page now states that type 2 diabetes runs strongly in families and that family history is among the strongest predictors, rather than leaving the inheritance question answered only by a note that it is not contagious.
- On the sixth, race and ethnicity framing. The higher prevalence in the listed groups remains stated as fact, now paired with the explanation that this reflects how risk, food environments, stress exposure and access to care are distributed rather than race being a biological cause in itself.
- On the seventh, emergencies. The generic 911 list has been replaced with diabetes-specific guidance: severe hyperglycemia with vomiting, deep rapid breathing, drowsiness or confusion, and severe hypoglycemia where the person cannot swallow safely, including the instruction not to put anything into their mouth.
- The suggested symptom polish has also been adopted, with recurrent infections added and the symptom list reorganised into common signs and other clues. We have additionally added fourteen research deep dives covering insulin resistance, beta-cell decline, diagnosis, A1C, medicines, hypoglycemia, monitoring, eating, exercise and remission, complications screening, prediabetes and prevention.
- One point of our own, beyond the review's scope. The review did not raise unexplained weight loss, which is a classic symptom of significant hyperglycemia and a clue that the diagnosis may be type 1 rather than type 2. It now appears on the page.
Download the PDF
Our reviewed pages on this
All source documents